Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Q: The deal would repeal a cost-control measure in “Obamacare” known as the Cadillac Tax, an unpopular levy on benefit-rich health insurance plans scheduled to take effect in 2022. That means Congress is upsetting the balance between expanding access and controlling costs that former President Barack Obama tried to strike in his signature law, said Kathleen Sebelius, who served as his health secretary. “President Obama thought it was very important to have additional access paid for,” said Sebelius. “This just takes a big step backwards.” The deal was reached in late stage negotiations between congressional leaders and Treasury Secretary Steven Mnuchin as part of a broader agreement to keep the government operating past this weekend. As part of the package, the Trump administration would be barred from using its rule-making authority to take certain actions that would destabilize the ACA’s health insurance markets. But it punts on the two biggest consumer health care issues this year: curbing prescription drug costs and ending surprise medical bills. Lawmakers will try again early next year — when another round of budget legislation is due. The Cadillac Tax was intended as a levy on the most generous plans, pegged at 40% of the value above a certain threshold. In 2022 that threshold would have been $11,200 for single coverage and $30,100 for a family plan, according to the nonpartisan Kaiser Family Foundation. One in five employers would have been affected. The tax was widely supported by economists and health policy experts, who argued it would help confront the problem of high U.S. health care spending. That’s because employers were expected to scale back their plans or shift costs to workers to avoid paying. Many employers and labor unions opposed it from the beginning. “It could have meant higher deductibles for employees or less choice,” said Cynthia Cox, who leads research on the Obama health law at the Kaiser Foundation. Repeal will “have a positive effect on a lot of people with health insurance coverage.” But critics said taxpayers will be on the hook for more debt, since repeal of the Cadillac tax and two other unpopular “Obamacare” levies is estimated to add about $400 billion to the federal deficit over 10 years. “The Cadillac tax may have resulted in some modest cost increases when it took effect, but what it was actually going to do is reduce health care costs, which would have raised wages,” said Marc Goldwein, of the nonpartisan Committee for a Responsible Federal Budget, which advocates for reining in the nation’s $1-trillion deficit. Here’s an overview of some of the other major health care components of the budget deal: — Also repeals the health law’s health insurance tax and its sales tax on medical devices. These taxes were intended to help pay for the cost of expanding coverage under the health law, which currently provides insurance to about 20 million people. Even without these taxes, most of the law’s financing stays in place. —Blocks the Trump administration from issuing regulations that would end the health law’s automatic re-enrollment provision, or from shutting down a state-level workaround called “silver loading,” which has helped stabilize “Obamacare”premiums. —Extends and increases Medicaid funding for U.S. territories, including Puerto Rico.

A: Budget deal puts access to health care above curbing costs.
****
Q: Chaiya, under pressure from health activists and doctors who campaigned to have him sacked, said declaring compulsory licenses on the drugs would save Thailand more than 3 billion baht ($100 million) over the next five years. “The findings have convinced me to go ahead with the CLs since the ministry’s policy is to give patients good access to quality drugs at cheap prices,” Chaiya said of the review by a panel of Health Ministry officials. The decision is a blow to major pharmaceutical companies which had lobbied hard to reverse the CL policy launched by the previous government appointed after a bloodless 2006 coup. The three drugs are Letrozole, a breast cancer medicine made by Novartis AG, the breast and lung cancer drug Docetaxel by Sanofi-Aventis, and Roche’s Erlotinib, used for treating lung, pancreatic and ovarian cancer. A license issued on a leukemia drug, Glivec, was cancelled last month after its maker, Novartis, agreed to supply it free to hundreds of Thai patients. Shortly after a democratically-elected government took power in February, Chaiya ordered the review of a policy he said was a “politically correct decision, but not legally correct”. At the time he said the government could afford the full cost of the drugs, if it meant avoiding trade retaliation by the United States, home to some of the world’s biggest drug firms. U.S. officials denied there were any plans to impose sanctions on Bangkok, although Thailand was placed on a watch list, meaning Washington believed its respect for patents had weakened. When Chaiya, a businessman with no medical training, fired the Health Ministry’s top official negotiating cheaper prices from foreign drug firms, outraged health activists and doctors launched a campaign to remove him. Chaiya said on Monday the ministry would buy cheaper versions of the cancer drugs from generic producers, such as Indian firms which already supply copy-cat HIV-AIDS medicines to Thailand. Under World Trade Organisation rules, countries can issue a compulsory license to make or buy generic versions of patented drugs deemed critical to public health as long as the medicines are meant for domestic use. Former Health Minister Mongkol na Songkhla overrode Merck’s AIDS drug Efavirenz in late 2006, arguing that Thailand could not afford patented drugs for a national health plan that covers about 80 percent of the country’s 63 million people. A few months later he did the same on a Sanofi-Aventis heart medicine and an AIDS drug made by Abbott Laboratories, which refused to register several new medicines in Thailand. Mongkol, who targeted the four cancer drugs weeks before he left office, has defended the CL policy against major drug firms which accused him of stealing their intellectual property rights. ($1= 30 Baht)

A: Thailand will override cancer drug patents.
****
Q: Employees of Novartis Pharma K.K. (NPKK) transferred some data from research centers to a Tokyo hospital when that data should have been sent directly without first passing through Novartis hands, according to a report by Japanese broadcaster NHK that was picked up by the Wall Street Journal. “NPKK is currently investigating the allegations,” Novartis said in a statement. The data was from a not yet fully enrolled 55-patient trial testing the Novartis cancer drug Tasigna, the company said. “Novartis Pharma K.K. is aware of the media report regarding a small investigator-initiated clinical study ... conducted to assess side effects in patients with chronic myelocytic leukemia,” Novartis said in a statement. “NPKK has conducted employee trainings on proper protocol related to investigator-initiated clinical studies and believes that any involvement of our medical representatives in investigator-initiated clinical studies is inappropriate.”  The University of Tokyo Hospital said it was re-examining test results it had received but had uncovered no evidence that Novartis employees had manipulated any of the data during the transfers, according to the Wall Street Journal report.

A:
Novartis employees may have violated trial protocol in Japan.
****